RadioMedix, Inc.
RadioMedix, Inc., headquartered in the United States, is a pioneering force in the radiopharmaceutical industry, specialising in the development and commercialisation of innovative diagnostic and therapeutic solutions. Founded in 2011, the company has made significant strides in advancing targeted radiotherapy, particularly in oncology, with a focus on improving patient outcomes. With a robust portfolio of unique products, including radiolabelled agents for imaging and treatment, RadioMedix stands out for its commitment to precision medicine. The company operates primarily in North America, with expanding influence in global markets. Recognised for its cutting-edge research and development, RadioMedix has established a strong market position, contributing to the evolution of personalised cancer care through its state-of-the-art technologies.
DitchCarbon Score
How does RadioMedix, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
RadioMedix, Inc.'s score of 41 is higher than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
RadioMedix, Inc.'s reported carbon emissions
In 2023, RadioMedix, Inc. reported total carbon emissions of approximately 2,084,437,000 kg CO2e. This figure includes Scope 1 emissions of about 175,687,000 kg CO2e, which encompass direct emissions from owned or controlled sources, and Scope 2 emissions of approximately 162,977,000 kg CO2e, representing indirect emissions from the generation of purchased electricity. The majority of their emissions, about 1,745,773,000 kg CO2e, fall under Scope 3, which includes upstream and downstream transportation and distribution. Comparatively, in 2022, the company recorded total emissions of around 1,964,588,000 kg CO2e, with Scope 1 emissions at about 188,734,000 kg CO2e and Scope 2 emissions at approximately 166,880,000 kg CO2e. Scope 3 emissions for that year were about 1,608,974,000 kg CO2e. Despite these substantial figures, RadioMedix, Inc. has not disclosed any specific reduction targets or initiatives as part of their climate commitments. There are no reported SBTi (Science Based Targets initiative) reduction targets or other formal climate pledges. The absence of reduction initiatives suggests that the company may be in the early stages of developing a comprehensive climate strategy. Overall, RadioMedix, Inc. is actively monitoring its carbon footprint across all scopes but currently lacks defined targets for emissions reduction.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 248,259,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 231,021,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 1,459,194,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
RadioMedix, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
